Physician profile
Michael Desimone
NPI 1609219369
$5,041.10
in general payments reported to CMS, 2019-2025
21 companies · $2,006 in 2025
The $2,006 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $162 · 2022: $584 · 2023: $680 · 2024: $1,609 · 2025: $2,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,295.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,737.91 | 2021-2025 | Rinvoq, Skyrizi, Creon |
| Gilead Sciences, INC. | $539.73 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $466.90 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $430.44 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $427.75 | 2021-2025 | Entyvio, Eohilia |
| Pfizer INC. | $253.74 | 2023-2025 | |
| Boston Scientific Corporation | $177.53 | 2022-2024 | Captivator II |
| Celgene Corporation | $163.95 | 2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $156.23 | 2024-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $151.28 | 2024-2025 | Iqirvo |
| Janssen Scientific Affairs, LLC | $126.93 | 2024 | Stelara |
| Genzyme Corporation | $80.75 | 2025 | |
| Ferring Pharmaceuticals INC. | $74.96 | 2022-2025 | Rebyota |
| Stryker Corporation | $68.59 | 2024 | Neptune |
| Intercept Pharmaceuticals, INC. | $47.11 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $37.55 | 2024 | Zymfentra |
| Madrigal Pharmaceuticals | $26.45 | 2024 | Resmetirom |
| Fujifilm Healthcare Americas Corporation | $25.60 | 2023 | Fujifilm |
| Ardelyx, INC. | $17.18 | 2023 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $15.96 | 2024 | Voquezna |
| Medtronic, INC. | $14.56 | 2025 | Gi Genius |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Desimone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.